Foundations Investment Advisors LLC Makes New Investment in Axon Enterprise, Inc. (NASDAQ:AXON)

Foundations Investment Advisors LLC bought a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 552 shares of the biotechnology company’s stock, valued at approximately $221,000.

A number of other hedge funds and other institutional investors have also modified their holdings of AXON. Whittier Trust Co. of Nevada Inc. increased its holdings in Axon Enterprise by 3.8% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 8,290 shares of the biotechnology company’s stock worth $3,312,000 after purchasing an additional 301 shares during the last quarter. Whittier Trust Co. increased its stake in shares of Axon Enterprise by 5.0% in the third quarter. Whittier Trust Co. now owns 15,820 shares of the biotechnology company’s stock worth $6,321,000 after buying an additional 756 shares during the last quarter. Everence Capital Management Inc. acquired a new stake in Axon Enterprise in the third quarter valued at $543,000. Toth Financial Advisory Corp boosted its stake in Axon Enterprise by 35.7% during the 3rd quarter. Toth Financial Advisory Corp now owns 475 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 125 shares during the last quarter. Finally, Heritage Wealth Management Inc. CA acquired a new position in Axon Enterprise during the 3rd quarter worth $269,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on AXON. Craig Hallum lifted their price target on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group raised their price objective on Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday. JMP Securities lifted their price objective on shares of Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Barclays increased their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Bank of America assumed coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $382.85.

Axon Enterprise Price Performance

Shares of AXON opened at $444.52 on Friday. Axon Enterprise, Inc. has a one year low of $199.29 and a one year high of $455.17. The stock’s fifty day moving average is $396.09 and its 200-day moving average is $336.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a market capitalization of $33.55 billion, a price-to-earnings ratio of 129.98, a price-to-earnings-growth ratio of 12.05 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.80 EPS. Equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Insiders Place Their Bets

In other news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the transaction, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, President Joshua Isner sold 25,811 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total transaction of $9,287,830.24. Following the completion of the transaction, the president now owns 228,166 shares in the company, valued at approximately $82,103,253.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now directly owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock worth $137,000,162 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.